Search results for: Chronic Diseases
Filter search results
Hospital Acquired Infection
8 January 1997
‘About one in ten patients in acute hospitals at any one time has an infection acquired after admission to hospitals’ (DH/PHLS, 1995, pi). This quotation, introducing recent guidance on the…
Tuberculosis
1 October 1998
The first Office of Health Economics (OHE) disease state booklet, written in 1962, was entitled ‘Progress against Tuberculosis’ and was published at a time of great optimism among health care…
Incentives for New Drugs to Tackle Anti-Microbial Resistance
1 May 2017
Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage companies to undertake R&D…
Additional Elements of Value for Health Technology Assessment Decisions
1 May 2017
Antimicrobial resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective. Antimicrobial resistance…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
1 October 2017
This briefing provides a detailed summary of a symposium held at the HTAi 2017 meeting in Rome. This briefing provides a detailed summary of a symposium held at the HTAi…
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
Using a multidisciplinary methodological approach combining a theoretical economic framework with uptake/market share analyses by country and interviews, this OHE research concludes that: (i) IP incentives for R&D may have…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel, global antibiotic development pipelines…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions
1 January 2020
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct…
Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?
3 January 2020
Meningococcal disease is a life-threatening infection and can result in severe sequelae. Recent scientific and technical advances have led to the discovery and implementation of novel meningococcal vaccines which have…